IN THIS issue of the ARCHIVES, Green1 elegantly reviews clinical issues about the potential use of marijuana and cannabinoids in glaucoma therapy. This editorial deals briefly with the scientific foundation underlying the marijuana-glaucoma controversy, and like the review, concludes that data, not demagoguery, should guide our path.
Glaucoma results in the degeneration of retinal ganglion cells and their optic nerve axons that carry visual impulses from the eye to the brain. Marijuana and cannabinoids affect the major risk factor for glaucoma, elevation of intraocular pressure (IOP), which is regulated by the hydrodynamic systems at the front of the eye.
Kaufman PL. Marijuana and Glaucoma. Arch Ophthalmol. 1998;116(11):1512-1513. doi:10.1001/archopht.116.11.1512